Compare FSBW & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | VNDA |
|---|---|---|
| Founded | 1936 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.7M | 441.5M |
| IPO Year | 2012 | 2006 |
| Metric | FSBW | VNDA |
|---|---|---|
| Price | $43.51 | $8.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $44.00 | $13.63 |
| AVG Volume (30 Days) | 8.2K | ★ 2.8M |
| Earning Date | 01-21-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.09 | N/A |
| Revenue | $140,954,000.00 | ★ $212,074,000.00 |
| Revenue This Year | $10.46 | $12.01 |
| Revenue Next Year | $4.42 | $24.28 |
| P/E Ratio | $10.62 | ★ N/A |
| Revenue Growth | 1.07 | ★ 11.12 |
| 52 Week Low | $34.61 | $3.81 |
| 52 Week High | $44.22 | $9.60 |
| Indicator | FSBW | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.77 | 61.30 |
| Support Level | $41.21 | $7.14 |
| Resistance Level | $42.26 | $7.82 |
| Average True Range (ATR) | 0.82 | 0.44 |
| MACD | 0.14 | -0.05 |
| Stochastic Oscillator | 89.47 | 62.09 |
FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.